Potency and toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Abstract

Chimeric antigen receptor (CAR) T cells have opened up a new model for the treatment of relapsed and/or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). However, CAR T cell therapy can cause severe or even fatal related toxicity that impairs the survival benefits of patients. Thus, developing and formulating the standardized clinical management of these toxicities are urgent for medics. Of note, potency and toxicity of CAR-T cells therapy are related to patient and disease features, the CAR-T product and escape of tumor cell. However, the optimal patient selection has not yet been well established.